Pipeline

The Phase III programs – POLAR-M and POLAR-A

The POLAR Phase III-study

The Phase III program for PledOx® consists of two double-blinded, randomized, placebo-controlled trials – POLAR-M and POLAR-A.

POLAR-M comprises 420 patients with metastatic colorectal cancer undergoing chemotherapy with FOLFOX (containing oxaliplatin) and will be conducted in Asia, Europe and the US. The trial will compare PledOx® at doses of 2 µmol/kg and 5 µmol/kg, respectively, with a placebo.

POLAR-A comprises 280 patients with colorectal cancer undergoing adjuvant chemotherapy with FOLFOX (containing oxaliplatin) and will be conducted in Asia and Europe. The trial will compare PledOx® at a dose of 5 µmol/kg with a placebo.

The first patient was enrolled in November 2018.

Share

Facebook
Twitter
LinkedIn
RSS

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com